Latanoprost Plus Timolol Stada (Latanoprost, Timolol)

• Latanoprost Plus Timolol is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family.
• Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage.
• Ocular hypertension: reduces elevated eye pressure to lower risk of developing glaucoma.
• Pseudoexfoliative glaucoma: helps control pressure in this secondary form.

• Latanoprost binds to prostaglandin F receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. Timolol blocks β‑adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production. The combined actions result in a net reduction of intra‑ocular pressure.

The ocular combination may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Eye redness (hyperemia)
• Increased eyelash growth
• Eye irritation or foreign body sensation
• Blurred vision
• Dry eye
• Mild ocular discomfort

Serious or Rare Side Effects

• Severe allergic reaction (angio‑edema, anaphylaxis)
• Significant bradycardia or heart block
• Bronchospasm in patients with asthma or COPD
• Marked deepening of the upper eyelid (ptosis)
• Persistent corneal edema
• Systemic hypotension

• When prescribing Latanoprost Plus Timolol, clinicians should consider several safety measures.
• Cardiovascular assessment: evaluate heart rate and blood pressure before initiating therapy.
• Respiratory status: avoid use in patients with asthma or severe chronic obstructive pulmonary disease.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Concurrent ocular medications: stagger administration to prevent washout effects.
• Systemic beta‑blocker use: monitor for additive bradycardic effects.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost Plus Timolol may interact with other medicines, requiring attention to avoid reduced efficacy or increased adverse effects.

Major Interactions (Avoid)

• Other systemic beta‑blockers: may cause excessive bradycardia or hypotension.
• Inhaled or oral sympathomimetics (e.g., epinephrine): may reduce ocular hypotensive effect.
• Topical ocular anesthetics: can increase corneal toxicity when combined.
• MAO inhibitors: potential for enhanced cardiovascular effects.
• Non‑selective beta‑blocker eye drops: risk of additive systemic absorption.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers: may potentiate hypotensive response.
• Anticholinergic eye drops: possible reduced efficacy of prostaglandin component.
• Systemic antihypertensives: monitor blood pressure.
• Other prostaglandin analogs: risk of additive ocular irritation.
• Corticosteroid eye drops: may diminish intra‑ocular pressure lowering.